Sovremennye podkhody k lecheniyu dislipidemiy: differentsirovannaya gipolipidemicheskaya terapiya


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The article considers the issues of differential treatment of various dyslipidemias with the purpose of prevention of atherosclerosis and its complications. The main classes of lipid-lowering drugs and characteristics of their use depending on the cardiovascular risk and type of dyslipidemia are presented.

全文:

受限制的访问

作者简介

V. Lupanov

参考

  1. Reiner Z., Catapano A.L., De Backer G., et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32(14):1769-818.
  2. Mills E.J., Rachlis B., Wu P., et al. Primary prevention of cardiovascular mortality and events with statin treatments. A network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008;52:1769-81.
  3. Эффективность и безопасность лекарственной терапии при первичной и вторичной профилактике сердечно-сосудистых заболеваний. ВНОК, 2011 //Рациональная Фармакотерапия в кардиологии 2011. № 7 (5) Прил. С. 2-72.
  4. Brugts J.J., Yetgin T., Hoeks S.E., et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomized controlled trials. BMJ 2009;338:b2376.
  5. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S): Scandinavian Simvastatin Survival study Group. Lancet 1994;344:1383-89.
  6. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
  7. Reiner Z. Combined therapy in the treatment of dyslipidemia. Fundam Clin Pharmacol 2010;24:19-28.
  8. Conroy R., Pyorala K., Fitzgerald A.P., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.
  9. Tyroler H.A. Cholesterol and cardiovascular disease. An overview of Lipid Research Clinics (LRC) epidemiologic studies as background for the LRC Coronary Primary Prevention Trial. Am J Cardiol 1984;54:14-109.
  10. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in Coronary Drug Project patients: long term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55.
  11. Keech A., Simes R.J., Barter P., et al. The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.
  12. Bruckert E., Labreuche J., Amarenco P. Metaanalysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010; 210:353-61.
  13. Balk E.M., Lichtenstein A.H., Chung M., et al. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006;189:19-30.
  14. Yokoyama M., Origasa H., Matsuzaki M., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised openlabel blinded endpoit analysis. Lancet 2007;369:1090-98.
  15. McKenney J.M., Jones P.H., Bays H.E., et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007;192:432-37.
  16. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.
  17. Davidson M.H., Stein E.A., Bays H.E., et al. COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding rescription omega-3-fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007;29:1354-67.
  18. Аронов Д.М., Лупанов В.П. Атеросклероз и коронарная болезнь сердца. Изд. 2-е, переработ. М., 2009. 248 с.
  19. Кардиоваскулярная профилактика. Национальные рекомендации. Разработаны Комитетом экспертов ВНОК, Москва 2011 // Кардиоваск. терапия и профилактика 2011. № 10 (6). Прил. 2. С. 1-64.
  20. Кухарчук В.В. Комментарий к последней версии рекомендаций "Руководство по лечению дислипидемий", подготовлен ного Рабочей группой по лечению дислипидемий ЕКО и ЕОА при участии Европейской ассоциации профилактики сердечно-сосудистых заболеваний // Атеросклероз и дислипидемии 2011. № 4. C. 70-2.
  21. Barter P.J., Caulfield M., Eriksson M., et al. ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##